Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Nasr City P.O. Box 29, Cairo, 11765, Egypt.
Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Nasr City P.O. Box 29, Cairo, 11765, Egypt.
Eur J Med Chem. 2020 Aug 15;200:112449. doi: 10.1016/j.ejmech.2020.112449. Epub 2020 May 16.
In the present work, we report the design and synthesis of a set of iodinated quinazolinones carrying benzenesulfonamide moiety as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. The target compounds showed promising inhibitory activity against the four examined human (h) CA isoforms; I, II, IX and XII. Compounds 4-18 displayed variable inhibition constants, ranging as follows: 7.6-782.8 nM for hCA I, 34.4-412.1 nM for hCA II, 29.1-2225.3 nM for hCA IX and 8.8-429.4 nM for hCA XII. Compound 9, the most potent against the tumor-specific CA IX/CA XII (K = 29.1 and 8.8 nM) gives the possibility to evaluate its cytotoxicity and selectivity in vitro against HepG-2, HCT-116 and MCF-7 cancer cell lines. Compound 9 showed significant cytotoxicity against the tumor cell lines (IC = 1.78, 1.94 and 3.07 μM, respectively) and relatively lower toxicity against WI38 normal cell line. The radiosensitizing activity of compound 9 was evaluated and displayed an increase in the radiation-induced cell death in cancer cells after receiving a single dose of 8 Gy gamma radiation. Thus, radiation was able to enhance the antiproliferative activity of compound 9. Molecular docking of 9 into the active site of CA IX and XII revealed the key interactions that could explain its potent activity and selectivity towards these isoforms.
在本工作中,我们报告了一组带有苯磺酰胺部分的碘代喹唑啉酮的设计和合成,作为碳酸酐酶(CA,EC 4.2.1.1)抑制剂。这些目标化合物对四种人(h)CA 同工酶(I、II、IX 和 XII)表现出有希望的抑制活性。化合物 4-18 显示出可变的抑制常数,范围如下:对 hCA I 为 7.6-782.8 nM,对 hCA II 为 34.4-412.1 nM,对 hCA IX 为 29.1-2225.3 nM,对 hCA XII 为 8.8-429.4 nM。对肿瘤特异性 CA IX/CA XII 最有效的化合物 9(K = 29.1 和 8.8 nM)使得能够评估其在 HepG-2、HCT-116 和 MCF-7 癌细胞系中的体外细胞毒性和选择性。化合物 9 对肿瘤细胞系表现出显著的细胞毒性(IC = 1.78、1.94 和 3.07 μM),对 WI38 正常细胞系的毒性相对较低。化合物 9 的放射增敏活性进行了评估,并显示在接受单次 8 Gy 伽马辐射后,癌细胞中辐射诱导的细胞死亡增加。因此,辐射能够增强化合物 9 的抗增殖活性。9 进入 CA IX 和 XII 的活性位点的分子对接揭示了能够解释其对这些同工酶的有效活性和选择性的关键相互作用。